Standard Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Standard Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15	Closed	-$3K	–	637
2021 Q1	$3K	Hold	15	–	–	﹤0.01%	376
2020 Q4	$4K	Buy	+15	New	+$3.44K	﹤0.01%	340

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Standard Family Office's VRTX Position: Q2 2021 in Review

Standard Family Office sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 15 shares — an estimated $3K sold.

Standard Family Office first reported a position in VRTX in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q4 2020. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Standard Family Office reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Standard Family Office sold 15 Vertex Pharmaceuticals shares in Q2 2021, an estimated $3K.
Standard Family Office first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Standard Family Office's Vertex Pharmaceuticals position peaked at $4K in Q4 2020.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Standard Family Office's 13F filing for Q2 2021, filed 13 Aug 2021.